Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Breast and Ovarian Cancer Risk After BRCA1 and BRCA2 Testing

Lifetime breast and ovarian cancer risk varied sharply after BRCA testing, with family history further shaping risk even when results were VUS or negative.

By Dr. Revathy Mohan V.R., MBBS · Oct 22, 2026 · 6 min read

Oncology·PLOS Med

RBA Targets c-KIT in Anaplastic Thyroid Cancer Study

Network pharmacology, docking, and cell experiments suggest RBA suppresses c-KIT signaling and limits KHM-5M anaplastic thyroid cancer cell…

Oct 22, 2026

Oncology·PLOS Med

South Korea cancer screening proxy rates shifted after COVID-19

Screening-derived proxy rates for solid cancers in South Korea changed after COVID-19, with forecasts suggesting uneven recovery across…

Oct 22, 2026

Oncology·Sci Transl Med

Type I Photodynamic Therapy Gains Ground in Hypoxic Tumors

A review of organic framework-based type I photosensitizers details oxygen-independent ROS generation and design strategies for hypoxic tumors.

Oct 22, 2026

Oncology·Cancer Disc

Tumor Growth Modeling in Mice Refines Biomarker and Drug Mechanism Studies

A 30,000-mouse analysis identifies the best tumor growth model and shows how modeling can sharpen biomarker discovery and…

Oct 22, 2026

Oncology·Gut

PCK1 Loss Drives MASH-HCC Through 12-HETE CD8 T Cell Dysfunction

PCK1 deficiency worsened MASH-HCC in preclinical models by fueling 12-HETE-driven CD8+ T cell dysfunction and weakening anti-PD-1 activity.

Oct 22, 2026

Oncology·Gut

Metastatic Colorectal Cancer: Emerging Systemic Treatment Concepts

A Gut review examines metastatic colorectal cancer therapy, current systemic standards, and emerging strategies to sensitize microsatellite stable…

Oct 22, 2026

Oncology·JNCI

JNCI correction on dyadic distress in cancer survivors and partners

JNCI issued a correction to a study on dyadic sexual and relationship distress in cancer survivors and partners,…

Oct 22, 2026

Oncology·JCO

Anal carcinoma mortality trends studied in U.S. CDC WONDER analysis

Population-based CDC WONDER analysis examines U.S. anal carcinoma mortality trends from 1999 to 2023, focusing on national burden…

Oct 22, 2026

Oncology·JCO

Alveltamig dose optimization study updated at ASCO

Only the study title is available in the feed, leaving the updated alveltamig dose-optimization results and endpoints unavailable…

Oct 22, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.